Patent is purely a recognition of intellectual property and rights, and in terms of price-sensitivity has no weight. Approval for distribution in a certain jurisdiction however, is very price-sensitive.
And even then, FDA approval is all that really matters for Cortical.
FDA approval is the chief authority globally, especially given the extensive Mutual Recognition Agreements (MRA) the FDA has with overseas regulatory bodies.
So I wouldn't even think about Cortical unless some news from the FDA appears.
Patent is purely a recognition of intellectual property and...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BPH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(7.69%) |
Mkt cap ! $14.46M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.3¢ | 1.1¢ | $36.14K | 3.087M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 34 | 8458638 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 530346 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| BPH (ASX) Chart |